Bayer Buys More Crispr Stock After Celgene Sells – Barron’s
Barron’s |
Bayer Buys More Crispr Stock After Celgene Sells
Barron’s Both Bayer and Celgene invested in Crispr before the company went public. A Bayer unit agreed in December 2015 to create a joint venture to discover and commercialize therapeutics to treat blood disorders, blindness and heart disease, other indications … Reviewing Crispr Therapeutics (NASDAQ:CRSP) and Iqvia (IQV) Should You Invest in CRISPR Therapeutics AG (CRSP)? A Look at the Insider Trends Analysts' Views: Government Properties Income Trust (GOV) and Crispr Therapeutics Ag (CRSP) |
